Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I

The American Journal of Cardiology
M DavidsonD Black

Abstract

This double-blind study to evaluate long-term efficacy and safety of atorvastatin was performed in 31 community- and university-based research centers in the USA to directly compare a new 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (reductase inhibitor) to an accepted drug of this class in patients with moderate hypercholesterolemia. Participants remained on a cholesterol-lowering diet throughout the study. One thousand forty-nine patients were randomized to receive atorvastatin 10 mg, lovastatin 20 mg, or placebo. At 16 weeks the placebo group was randomized to either atorvastatin or lovastatin treatment. At 22 weeks, patients who had not met low-density lipoprotein (LDL) cholesterol target levels doubled the dose of reductase inhibitor. Efficacy evaluation was mean percent change from baseline in LDL cholesterol, triglycerides, total cholesterol, high-density-lipoprotein cholesterol, and apolipoprotein B (apoB). Safety profiles as determined by change from baseline in laboratory evaluations, ophthalmologic parameters, and reporting of adverse events were similar for the 2 reductase inhibitors. After 52 weeks, the atorvastatin group maintained a significantly greater reduction in LDL cholesterol (-37% vs -29%), t...Continue Reading

References

Jan 1, 1994·European Journal of Clinical Pharmacology·R LaaksonenJ J Himberg

❮ Previous
Next ❯

Citations

Mar 14, 2001·The American Journal of Cardiology·J H Stein, P E McBride
Sep 21, 2001·The American Journal of Cardiology·D HunninghakeS Kafonek
Dec 16, 2005·The AAPS Journal·Jaap W MandemaDaniel Hartman
Jun 17, 2008·Cardiovascular Drugs and Therapy·Fergus McTaggart, Peter Jones
Jun 26, 1999·Atherosclerosis·J J Kastelein
Dec 23, 1998·Atherosclerosis·R S Rosenson, G D Lowe
Mar 20, 2001·Atherosclerosis·R S RosensonE J Schaefer
Aug 16, 2000·Atherosclerosis·C Otto, P Schwandt
Feb 12, 2005·The British Journal of Nutrition·Hui-Ting YangHsin-Ju Chou
Sep 28, 2005·International Journal of Cardiology·Mark HirschAnders Olsson
Aug 21, 2010·Current Atherosclerosis Reports·Emilie Mas, Trevor A Mori
Apr 5, 2001·Atherosclerosis. Supplements·J Dupuis
Nov 7, 2002·Circulation Journal : Official Journal of the Japanese Circulation Society·Pang H ChongCory Franklin
Mar 29, 2002·Kidney International·Kevin P G HarrisUNKNOWN Atorvastatin in CAPD Study Investigators. Continuous ambulatory peritoneal dialysis
Dec 31, 2002·The American Journal of Medicine·Joseph P FrolkisDennis L Sprecher
Aug 4, 2009·Journal of Clinical Lipidology·Michael A PacanowskiIssam Zineh
Jul 31, 2007·International Journal of Cardiology·Kwang Kon KohSeung Hwan Han
Dec 17, 2009·British Journal of Clinical Pharmacology·David J HealSharon L Smith
May 12, 2010·Journal of Clinical Pharmacy and Therapeutics·T-C WengS-H Tai
Jul 4, 2002·Current Medical Research and Opinion·Evagelos RizosMoses Elisaf
Jul 18, 2003·The American Journal of Cardiology·Robert S Rosenson, Wolfgang Koenig
Jul 9, 2004·Scandinavian Journal of Immunology·K T LappegårdT E Mollnes
Jul 5, 2005·Expert Opinion on Investigational Drugs·G R Thompson, R P Naoumova
Mar 7, 2003·Journal of Atherosclerosis and Thrombosis·Yuji YoshitomiUNKNOWN National Cholesterol Education Program
Sep 20, 2002·Journal of Atherosclerosis and Thrombosis·Eriko MorishitaShinji Nakao
Jun 15, 2007·Journal of the American College of Cardiology·Leo Marcoff, Paul D Thompson
Jun 25, 2016·Evidence-based Complementary and Alternative Medicine : ECAM·Woo-Sang JungKi-Ho Cho

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.